AcelRx Pharmaceuticals, Inc. (ACRX) Director Buys $15,100.00 in Stock
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Director Mark G. Edwards purchased 5,000 shares of the stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $3.02 per share, for a total transaction of $15,100.00. Following the completion of the transaction, the director now owns 115,200 shares of the company’s stock, valued at approximately $347,904. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) traded down 0.84% during midday trading on Friday, hitting $2.95. The stock had a trading volume of 1,136,886 shares. The company’s 50 day moving average price is $2.99 and its 200-day moving average price is $2.80. The firm’s market capitalization is $133.87 million. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $4.08.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. The business had revenue of $2.66 million during the quarter, compared to the consensus estimate of $2.63 million. Equities analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current year.
Hedge funds have recently bought and sold shares of the stock. ING Groep NV raised its stake in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the period. Acadian Asset Management LLC raised its stake in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the period. Teachers Advisors LLC raised its stake in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. Virtu KCG Holdings LLC raised its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Finally, LMR Partners LLP acquired a new stake in AcelRx Pharmaceuticals during the second quarter valued at about $319,000. 30.37% of the stock is currently owned by institutional investors.
Several brokerages have recently issued reports on ACRX. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 1st. Roth Capital reaffirmed a “buy” rating and issued a $12.50 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 10th. Zacks Investment Research raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Royal Bank Of Canada set a $6.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Friday. Finally, ValuEngine downgraded AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $7.50.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.